Last reviewed · How we verify

norepinephrine versus midodrine & octreotide

National Hepatology & Tropical Medicine Research Institute · FDA-approved active Small molecule

norepinephrine versus midodrine & octreotide is a Sympathomimetic amine / Alpha-1 adrenergic agonist / Somatostatin analog Small molecule drug developed by National Hepatology & Tropical Medicine Research Institute. It is currently FDA-approved for Acute variceal hemorrhage in portal hypertension, Prevention of variceal rebleeding in cirrhotic patients.

Norepinephrine acts as a sympathomimetic to increase blood pressure, while midodrine and octreotide are used as alternative or adjunctive agents to manage variceal bleeding and portal hypertension complications.

Norepinephrine acts as a sympathomimetic to increase blood pressure, while midodrine and octreotide are used as alternative or adjunctive agents to manage variceal bleeding and portal hypertension complications. Used for Acute variceal hemorrhage in portal hypertension, Prevention of variceal rebleeding in cirrhotic patients.

At a glance

Generic namenorepinephrine versus midodrine & octreotide
SponsorNational Hepatology & Tropical Medicine Research Institute
Drug classSympathomimetic amine / Alpha-1 adrenergic agonist / Somatostatin analog
TargetAlpha-1 adrenergic receptor / Beta-1 adrenergic receptor / Somatostatin receptor
ModalitySmall molecule
Therapeutic areaGastroenterology / Hepatology
PhaseFDA-approved

Mechanism of action

Norepinephrine is a catecholamine that stimulates alpha and beta-adrenergic receptors to increase systemic vascular resistance and blood pressure. Midodrine is an alpha-1 adrenergic agonist that increases peripheral vasoconstriction, while octreotide is a somatostatin analog that reduces splanchnic blood flow and portal pressure. This combination is used in acute variceal hemorrhage management to maintain hemodynamic stability and reduce rebleeding risk.

Approved indications

Common side effects

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Frequently asked questions about norepinephrine versus midodrine & octreotide

What is norepinephrine versus midodrine & octreotide?

norepinephrine versus midodrine & octreotide is a Sympathomimetic amine / Alpha-1 adrenergic agonist / Somatostatin analog drug developed by National Hepatology & Tropical Medicine Research Institute, indicated for Acute variceal hemorrhage in portal hypertension, Prevention of variceal rebleeding in cirrhotic patients.

How does norepinephrine versus midodrine & octreotide work?

Norepinephrine acts as a sympathomimetic to increase blood pressure, while midodrine and octreotide are used as alternative or adjunctive agents to manage variceal bleeding and portal hypertension complications.

What is norepinephrine versus midodrine & octreotide used for?

norepinephrine versus midodrine & octreotide is indicated for Acute variceal hemorrhage in portal hypertension, Prevention of variceal rebleeding in cirrhotic patients.

Who makes norepinephrine versus midodrine & octreotide?

norepinephrine versus midodrine & octreotide is developed and marketed by National Hepatology & Tropical Medicine Research Institute (see full National Hepatology & Tropical Medicine Research Institute pipeline at /company/national-hepatology-tropical-medicine-research-institute).

What drug class is norepinephrine versus midodrine & octreotide in?

norepinephrine versus midodrine & octreotide belongs to the Sympathomimetic amine / Alpha-1 adrenergic agonist / Somatostatin analog class. See all Sympathomimetic amine / Alpha-1 adrenergic agonist / Somatostatin analog drugs at /class/sympathomimetic-amine-alpha-1-adrenergic-agonist-somatostatin-analog.

What development phase is norepinephrine versus midodrine & octreotide in?

norepinephrine versus midodrine & octreotide is FDA-approved (marketed).

What are the side effects of norepinephrine versus midodrine & octreotide?

Common side effects of norepinephrine versus midodrine & octreotide include Hypertension, Tachycardia, Headache, Abdominal pain, Hyperglycemia, Peripheral ischemia.

What does norepinephrine versus midodrine & octreotide target?

norepinephrine versus midodrine & octreotide targets Alpha-1 adrenergic receptor / Beta-1 adrenergic receptor / Somatostatin receptor and is a Sympathomimetic amine / Alpha-1 adrenergic agonist / Somatostatin analog.

Related